Allergic Conjunctivitis - Pipeline Review, H2 2017

  • ID: 4419016
  • Report
  • 70 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • AlleCures Inc
  • Allergan Plc
  • Clevexel Pharma SAS
  • Griffin Discoveries BV
  • Ocular Therapeutix Inc
  • MORE
Allergic Conjunctivitis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2017, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 8 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • AlleCures Inc
  • Allergan Plc
  • Clevexel Pharma SAS
  • Griffin Discoveries BV
  • Ocular Therapeutix Inc
  • MORE
Introduction

Allergic Conjunctivitis - Overview

Allergic Conjunctivitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Allergic Conjunctivitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Allergic Conjunctivitis - Companies Involved in Therapeutics Development

Accolade Pharmaceuticals LLC

Aldeyra Therapeutics Inc

AlleCures Inc

Allergan Plc

Clevexel Pharma SAS

Griffin Discoveries BV

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Portola Pharmaceuticals Inc

Re-Pharm Ltd

Realm Therapeutics Plc

Sylentis SAU

Xencor Inc

Allergic Conjunctivitis - Drug Profiles

ADX-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-229666 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPC-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Allergic Conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-136 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-2761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-0217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYL-116011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-7195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zafi-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergic Conjunctivitis - Dormant Projects

Allergic Conjunctivitis - Discontinued Products

Allergic Conjunctivitis - Product Development Milestones

Featured News & Press Releases

Oct 16, 2017: Realm Therapeutics to Present Update on Drug Development Program PR013 at 2017 BIO Investor Forum

Oct 10, 2017: Aldeyra Therapeutics Announces New Data on ADX-102 at 2017 Research & Development Day

Sep 27, 2017: Aldeyra Therapeutics Announces 2017 Research and Development Day

Sep 21, 2017: Realm Therapeutics Provides Clinical Development Update on PR013

Sep 11, 2017: Realm Therapeutics - FDA Permits PR013 to Proceed to Phase II Trial

Sep 07, 2017: Realm Therapeutics to present update on PR013 at the Rodman & Renshaw 19th Annual Global Investment Conference

Aug 02, 2017: Realm Therapeutics Submits Investigational New Drug Application for PR013 for Allergic Conjunctivitis

Jul 06, 2017: Realm Therapeutics - Presentation at World Congress on Inflammation

Jun 14, 2017: Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing

Jun 14, 2017: Realm Therapeutics to present on PR013 at the 2017 Marcum Microcap Conference

Jun 13, 2017: Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial

Apr 18, 2017: Aldeyra Therapeutics Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial

Feb 07, 2017: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial

Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase

Dec 05, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Allergic Conjunctivitis, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, H2

Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H2

Allergic Conjunctivitis - Pipeline by AlleCures Inc, H2

Allergic Conjunctivitis - Pipeline by Allergan Plc, H2

Allergic Conjunctivitis - Pipeline by Clevexel Pharma SAS, H2

Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2

Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, H2

Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc, H2

Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals Inc, H2

Allergic Conjunctivitis - Pipeline by Re-Pharm Ltd, H2

Allergic Conjunctivitis - Pipeline by Realm Therapeutics Plc, H2

Allergic Conjunctivitis - Pipeline by Sylentis SAU, H2

Allergic Conjunctivitis - Pipeline by Xencor Inc, H2

Allergic Conjunctivitis - Dormant Projects, H2

Allergic Conjunctivitis - Discontinued Products, H2

List of Figures

Number of Products under Development for Allergic Conjunctivitis, H2

Number of Products under Development by Companies, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Accolade Pharmaceuticals LLC
  • Aldeyra Therapeutics Inc
  • AlleCures Inc
  • Allergan Plc
  • Clevexel Pharma SAS
  • Griffin Discoveries BV
  • Ocular Therapeutix Inc
  • Ohr Pharmaceutical Inc
  • Portola Pharmaceuticals Inc
  • Re-Pharm Ltd
  • Realm Therapeutics Plc
  • Sylentis SAU
  • Xencor Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll